Literature DB >> 31006772

[Methodology of the 2nd seroprevalence study in Spain].

Aurora Limia Sánchez1, María Vicenta Labrador Cañadas1, Fernando de Ory Manchón2, Laura Sánchez-Cambronero Cejudo1, Iria Rodríguez Cobo1,3, Elena Cantero Gudino1,3, Julio Vázquez Moreno1, Araceli Arce Arnáez1.   

Abstract

Seroprevalence studies are designed in population samples to assess the level and distribution of immunity induced by natural infection of certain infectious agents or by immunization against them. The purpose of the 2nd Seroprevalence Study in Spain is to assess the prevalence and distribution of immune status against vaccine-preventable diseases and generated by natural infection by other microorganisms. Pathologies specifically included in the study are: poliomyelitis, diphtheria, tetanus, pertussis, measles, rubella, mumps, varicella, invasive meningococcal disease by serogroup C, hepatitis A, hepatitis B, hepatitis E, hepatitis C and HIV. The study has a similar design of that conducted in 1996, as it is a descriptive cross-sectional study in resident population of 2 to 80 years of age in Spain. Two-stage conglomerate sampling was carried out on the population aged 2 to 80 years living in Spain, with an initial sample size of 10,000 people. The methodology of the study is described in this article.

Entities:  

Keywords:  Cross-sectional survey; Immunization program; Infectious diseases; Methodology; Program evaluation; Seroepidemiological study; Seroprevalence; Spain; Vaccination; Vaccine-preventable diseases

Mesh:

Year:  2019        PMID: 31006772

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  1 in total

1.  [Seroprevalence of antibodies against measles virus in Galicia: trends during the last ten years depending on age and sex].

Authors:  J J Costa-Alcalde; R Trastoy-Pena; G Barbeito-Castiñeiras; D Navarro de la Cruz; B Mejuto; A Aguilera
Journal:  Rev Esp Quimioter       Date:  2020-03-02       Impact factor: 1.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.